In RET-mutant medullary thyroid cancer, the overall response rate was 73% in first line treatment and 69% in the second, also showing it to be effective on CNS metastases and uncommon metastatic sites such as choroidal metastases [197,198]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.